LATEST

• REGULATORY MHLW Gives Kissei until July 21 to Report on Tavneos
  July 3, 2026

• REGULATORY Centrist Reform Alliance Warns US MFN Policy Poses “Real Crisis” for Drug Access
  July 3, 2026

• BUSINESS Sawai Prevails in ALS Drug Contract Appeal against Neugen
  July 3, 2026

• ORGANIZATION FPMAJ Sets Up Drug Security Task Force under Chairman
  July 3, 2026

• BUSINESS Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
  July 3, 2026

• BUSINESS Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
  July 3, 2026

• BUSINESS PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
  July 3, 2026

• BUSINESS PeptiDream Poaches 3 EVPs to Bolster Global Expansion
  July 3, 2026

• BUSINESS Eisai’s Dayvigo Accepted for UK Regulatory Review
  July 3, 2026

• BUSINESS Kowa Wins Hong Kong Approval for Livalo, Glanatec OK in Vietnam
  July 3, 2026

• BUSINESS Medinet Exercises Option for Stempeucel Rights in Japan
  July 3, 2026

• REGULATORY Ishin Urges Govt to Make Healthcare, Drug Innovation Core Growth Strategy
  July 3, 2026

• BUSINESS Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
  July 2, 2026

• REGULATORY MHLW Seeks Sponsors for 6 High-Need Unapproved, Off-Label Drugs
  July 2, 2026

• REGULATORY MHLW Orders Label Revisions for Four Pediatric Antibiotics
  July 2, 2026

• ORGANIZATION JETRO Opens 2026 Applications for Regenerative Medicine Program
  July 2, 2026

• BUSINESS Mochida Seeks Pediatric Expansion for Urece
  July 2, 2026

• BUSINESS Kowa Files US NDA for Nicox’s Glaucoma Drug
  July 2, 2026

• BUSINESS GNI Closes Acquisition of Ayumi Pharma
  July 2, 2026

• BUSINESS Toho to Acquire Ishin Pharma, Bring Allostem Distribution In-House
  July 2, 2026

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »